Marilyn Singleton, MD @MSingletonMDJD
Dexamethasone - Common Drug Improves COVID-19 Survival in Trial
https://twitter.com/MSingletonMDJD/status/1272934089377497088
_
Dexamethasone, the familiar glucocorticoid, reduced deaths in hospitalized COVID-19 patients with severe disease by one-third compared to those receiving usual care, according to topline interim results from the RECOVERY trial released early Tuesday.
https://www.medpagetoday.com/infectiousdisease/covid19/87086
_
Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19
In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Over 11,500 patients have been enrolled from over 175 NHS hospitals in the UK.
On 8 June, recruitment to the dexamethasone arm was halted since, in the view of the trial Steering Committee, sufficient patients had been enrolled to establish whether or not the drug had a meaningful benefit.
…
https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf